Could Viking Therapeutics Become the Next Eli Lilly?

Viking Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, has recently announced the initiation of a Phase 2 clinical trial for its lead candidate, VK2735, aimed at treating obesity and related metabolic disorders. This trial, which commenced in October 2023, is expected to enroll approximately 200 patients across multiple sites in the United States. The primary endpoint of the study is to evaluate the efficacy of VK2735 in reducing body weight over a 24-week treatment period. The announcement comes at a time when the obesity treatment market is gaining significant traction, with increasing demand for effective therapies. Viking's market capitalisation currently stands at approximately $250 million, reflecting a growing interest in its innovative approach to weight management.

The strategic context of this announcement is underscored by the competitive landscape in obesity therapeutics, which has seen a surge in investment and research activity. Companies like Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have successfully launched drugs that have generated substantial revenue, highlighting the commercial potential in this sector. Viking's VK2735 is designed to leverage a unique mechanism of action that differentiates it from existing therapies, potentially positioning the company as a significant player in the obesity treatment market. However, the success of this trial is crucial for Viking, as it will determine the viability of VK2735 and its subsequent development stages.

From a financial perspective, Viking Therapeutics reported a cash balance of approximately $45 million as of the end of Q2 2023, with a quarterly burn rate of around $7 million. This financial position suggests that the company has a funding runway of approximately six to seven months, which may be sufficient to complete the current clinical trial, assuming no unforeseen expenses arise. However, the company will need to consider future financing options to support ongoing development and potential commercialization efforts. The risk of dilution remains a concern, particularly if Viking is required to raise additional capital before achieving significant milestones or revenue generation.

In terms of valuation, Viking's current enterprise value is estimated at around $205 million, based on its market capitalisation and cash position. When compared to direct peers in the obesity treatment space, such as Zafgen Inc. (NASDAQ: ZFGN) and Rhythm Pharmaceuticals (NASDAQ: RYTM), Viking's valuation metrics appear relatively attractive. Zafgen, with a market cap of approximately $150 million, is trading at an enterprise value of around $120 million, while Rhythm Pharmaceuticals, valued at $1.2 billion, has an enterprise value of approximately $1.1 billion. This comparison highlights that Viking Therapeutics is positioned in a lower valuation bracket, which could suggest potential upside if VK2735 demonstrates positive clinical outcomes.

The execution track record of Viking Therapeutics has been mixed, with previous clinical trials yielding varying results. The company has historically faced challenges in advancing its pipeline, which raises questions about its ability to deliver on timelines and milestones. The initiation of the Phase 2 trial for VK2735 represents a critical juncture for the company, as it seeks to regain momentum and investor confidence. A specific risk associated with this announcement is the potential for adverse events or lack of efficacy during the trial, which could lead to significant setbacks and impact the company's valuation and funding prospects.

Looking ahead, the next measurable catalyst for Viking Therapeutics will be the interim results from the Phase 2 trial, expected in mid-2024. These results will be pivotal in determining the future trajectory of VK2735 and the company's overall strategy in the obesity market. A positive outcome could catalyse further investment and partnership opportunities, while negative results could lead to a reassessment of the company's pipeline and financial health.

In conclusion, the announcement regarding the initiation of the Phase 2 clinical trial for VK2735 is significant for Viking Therapeutics, as it marks a critical step in the development of a potentially transformative obesity treatment. However, the company's current financial position and the inherent risks associated with clinical trials necessitate careful scrutiny. The announcement can be classified as significant, given its potential implications for valuation and the future direction of the company in a competitive market.